Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Prilosec OTC Launch By July 2002 Predicted By P&G's Lafley

This article was originally published in The Tan Sheet

Executive Summary

Prilosec should be available without a prescription by July 2002, Procter & Gamble President/CEO A.G. Lafley told analysts during a June 15 teleconference.

You may also be interested in...



OTC Prilosec

Heartburn treatment should be available without a prescription by year-end, P&G CFO Clayton Daly says during Consumer Analyst Group of New York conference Feb. 22. "We're in ongoing discussions with FDA about labeling and dosing, and we believe we're moving in the right direction...in terms of getting that product approved later this year," he noted. P&G, which holds OTC marketing rights to AstraZeneca's Rx version, had predicted approval by July (1"The Tan Sheet" June 18, 2001, p. 6)...

OTC Prilosec

Heartburn treatment should be available without a prescription by year-end, P&G CFO Clayton Daly says during Consumer Analyst Group of New York conference Feb. 22. "We're in ongoing discussions with FDA about labeling and dosing, and we believe we're moving in the right direction...in terms of getting that product approved later this year," he noted. P&G, which holds OTC marketing rights to AstraZeneca's Rx version, had predicted approval by July (1"The Tan Sheet" June 18, 2001, p. 6)...

OTC Prilosec

Heartburn treatment should be available without a prescription by year-end, P&G CFO Clayton Daly says during Consumer Analyst Group of New York conference Feb. 22. "We're in ongoing discussions with FDA about labeling and dosing, and we believe we're moving in the right direction...in terms of getting that product approved later this year," he noted. P&G, which holds OTC marketing rights to AstraZeneca's Rx version, had predicted approval by July (1"The Tan Sheet" June 18, 2001, p. 6)...

Related Content

Topics

UsernamePublicRestriction

Register

PS092694

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel